Tandem Diabetes Care, a global diabetes technology company, announced the appointment of Jeannette Bankes as president and chief executive officer (CEO), and a member of its Board of Directors, effective November 16, 2026. Bankes will succeed John Sheridan, who will retire at the end of 2026 after more than a decade of service to Tandem, as part of a planned leadership transition.

Sheridan has served as Tandem’s president and CEO since 2019, after joining the Company as chief operating officer in 2013. During his tenure, Tandem launched a portfolio of automated insulin delivery solutions, while strengthening the organization’s ability to operate on a global scale, and has initiated business model changes to simplify and improve technology access. Mr. Sheridan will remain with the Company as an employee through the end of 2026, then will serve as a consultant to support a smooth transition.

Bankes brings more than 30 years of global operating experience and a strong record of translating strategy into consistent execution and growth. Her customer-focused approach and commitment to innovation align with Tandem’s mission and priorities as the Company advances its technology roadmap, broadens access and pursues sustainable, profitable growth. Her appointment follows a Board-led succession and search process designed to ensure continuity as Tandem executes its strategy.

“On behalf of the Board, I thank John for his significant contributions and dedication to our customers, employees and shareholders. He established Tandem as a global leader in diabetes technology and positioned the Company for its next phase of growth,” said Beckie Robertson, Chair of Tandem’s Board of Directors. “Jeannette is the right CEO to build on this foundation. Her broad operating experience, focus on the people we serve and ability to translate innovation into impact will be critical as we seek to deliver new technology and drive profitable growth.”